{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:56:12Z","timestamp":1792828572926,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12022-019-9568-5","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T08:21:40Z","timestamp":1548922900000},"page":"118-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors"],"prefix":"10.1007","volume":"30","author":[{"given":"Omalkhaire M.","family":"Alshaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia L.","family":"Asa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Mete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"9568_CR1","unstructured":"Asa SL. Tumors of the pituitary Gland. AFIP Atlas of Tumor Pathology, Series 4, Fascicle 15, Silverberg SG, editor. ARP Press, Silver Spring, MD, 2011."},{"key":"9568_CR2","first-page":"315","volume-title":"Endocrine Pathology","author":"SL Asa","year":"2016","unstructured":"Asa SL, Mete O. The Pituitary Gland. In: Mete O, Asa SL, editors. Endocrine Pathology. Cambridge: Cambridge University Press, 2016: 315\u2013397."},{"issue":"4","key":"9568_CR3","doi-asserted-by":"publisher","first-page":"C5","DOI":"10.1530\/ERC-17-0004","volume":"24","author":"SL Asa","year":"2017","unstructured":"Asa SL, Casar-Borota O, Chanson P, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 2017; 24(4):C5-C8.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"9568_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1586\/17446651.2016.1153422","volume":"11","author":"SL Asa","year":"2016","unstructured":"Asa SL, Ezzat S. Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. Expert Reviews Endocrinology and Metabolism 2016; 11(2):149\u2013162.","journal-title":"Expert Reviews Endocrinology and Metabolism"},{"key":"9568_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/1097-0142(19850201)55:3<598::AID-CNCR2820550320>3.0.CO;2-S","volume":"55","author":"BW Scheithauer","year":"1985","unstructured":"Scheithauer BW, Randall RV, Laws ER, Jr., Kovacs KT, Horvath E, Whitaker MD. Prolactin cell carcinoma of the pituitary. Clinicopathological, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases. Cancer 1985; 55:598\u2013604.","journal-title":"Cancer"},{"key":"9568_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2265.1986.tb01672.x","volume":"25","author":"JL Gabrilove","year":"1986","unstructured":"Gabrilove JL, Anderson PJ, Halmi NS. Pituitary pro-opiomelanocortin-cell carcinoma occurring in conjunction with a glioblastoma in a patient with Cushing\u2019s disease and subsequent Nelson\u2019s syndrome. Clin Endocrinol (Oxf) 1986; 25:117\u2013126.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9568_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0090-3019(87)90210-2","volume":"28","author":"M Kuroki","year":"1987","unstructured":"Kuroki M, Tanaka r, Yokoyama M, Shimbo Y, Ikuta F. Subarachnoid dissemination of a pituitary adenoma. Surg Neurol 1987; 28:71\u201376.","journal-title":"Surg Neurol"},{"key":"9568_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0046-8177(87)80200-9","volume":"18","author":"P Luzi","year":"1987","unstructured":"Luzi P, Miracco C, Lio R, et al. Endocrine inactive pituitary carcinoma metastasizing to cervical lymph nodes: a case report. Hum Pathol 1987; 18:90\u201392.","journal-title":"Hum Pathol"},{"key":"9568_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00000441-198908000-00007","volume":"298","author":"RB Mountcastle","year":"1989","unstructured":"Mountcastle RB, Roof BS, Mayfield RK, et al. Case Report: Pituitary adenocarcinoma in an acromegalic patient: response to bromocriptine and pituitary testing: a review of the literature on 36 cases of pituitary carcinoma. Am J Med Sci 1989; 298:109\u2013118.","journal-title":"Am J Med Sci"},{"key":"9568_CR10","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1210\/jcem-71-4-1068","volume":"71","author":"H Nawata","year":"1990","unstructured":"Nawata H, Higuchi K, Ikuyama S et al. Corticotropin-releasing hormone- and adrenocorticotropin-producing pituitary carcinoma with metastases to the liver and lung in a patient with metastases to the liver and lung in a patient with Cushing\u2019s disease. J Clin Endocrinol Metab 1990; 71:1068\u20131073.","journal-title":"J Clin Endocrinol Metab"},{"key":"9568_CR11","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/1097-0142(19911001)68:7<1605::AID-CNCR2820680723>3.0.CO;2-D","volume":"68","author":"DM Atienza","year":"1991","unstructured":"Atienza DM, Vigersky RJ, Lack EE, et al. Prolactin-producing pituitary carcinoma with pulmonary metastases. Cancer 1991; 68:1605\u20131610.","journal-title":"Cancer"},{"key":"9568_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2265.1992.tb02306.x","volume":"37","author":"PM Stewart","year":"1992","unstructured":"Stewart PM, Carey MP, Graham CT, Wright AD, London DR. Growth hormone secreting pituitary carcinoma: a case report and literature review. Clin Endocrinol (Oxf) 1992; 37:189\u2013195.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9568_CR13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/jnnp.55.12.1205","volume":"55","author":"T Petterson","year":"1992","unstructured":"Petterson T, MacFarlane IA, MacKenzie JM, Shaw MDM. Prolactin secreting pituitary carcinoma. J Neurol Neurosurg Psychiatry 1992; 55:1205\u20131206.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9568_CR14","first-page":"529","volume":"76","author":"AJ Mixson","year":"1993","unstructured":"Mixson AJ, Friedman TC, Katz DA, et al. Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab 1993; 76:529\u2013533.","journal-title":"J Clin Endocrinol Metab"},{"key":"9568_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/dc.2840110116","volume":"11","author":"DM Cartwright","year":"1994","unstructured":"Cartwright DM, Miller TR, Nasr AJ. Fine-needle aspiration biopsy of pituitary carcinoma with cervical lymph node metastases: a report of two cases and review of the literature. Diagn Cytopathol 1994; 11:68\u201373.","journal-title":"Diagn Cytopathol"},{"key":"9568_CR16","first-page":"81","volume":"141","author":"D L\u00fcdecke","year":"1995","unstructured":"L\u00fcdecke D, Saeger W. Carcinomas of the pituitary: definition and review of the literature. Gen Diagn Pathol 1995; 141:81\u201392.","journal-title":"Gen Diagn Pathol"},{"key":"9568_CR17","first-page":"93","volume":"119","author":"AR Frost","year":"1995","unstructured":"Frost AR, Tenner S, Tenner M, Rollhauser C, Tabbara SO. ACTH-producing pituitary carcinoma presenting as the cauda equina syndrome. Arch Pathol Lab Med 1995; 119:93\u201396.","journal-title":"Arch Pathol Lab Med"},{"key":"9568_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1227\/00006123-199510000-00027","volume":"37","author":"P Beauchesne","year":"1995","unstructured":"Beauchesne P, Trouillas J, Barral F, Brunon J. Gonadotropic pituitary carcinoma: case report. Neurosurg 1995; 37:810-815.","journal-title":"Neurosurg"},{"key":"9568_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/BF02739912","volume":"7","author":"W Saeger","year":"1996","unstructured":"Saeger W, L\u00fcdecke DK. Pituitary carcinomas. Endocr Pathol 1996; 7:21\u201335.","journal-title":"Endocr Pathol"},{"key":"9568_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1530\/eje.0.1370176","volume":"137","author":"AF Garr\u00e3o","year":"1997","unstructured":"Garr\u00e3o AF, Sobrinho LGOP, Bugalho MJ et al. ACTH-producing carcinoma of the pituitary with haematogenic metastases. European Journal of Endocrinology 1997; 137:176\u2013180.","journal-title":"European Journal of Endocrinology"},{"key":"9568_CR21","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3","volume":"79","author":"PJ Pernicone","year":"1997","unstructured":"Pernicone PJ, Scheithauer B, Sebo TJ, et al. Pituitary carcinoma: A clinicopathologic study of 15 cases. Cancer 1997; 79:804\u2013812.","journal-title":"Cancer"},{"key":"9568_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/BF03346909","volume":"20","author":"B Lormeau","year":"1997","unstructured":"Lormeau B, Miossec P, Sibony M, Valensi P, Attali JR. Adrenocorticotropin-producing pituitary carcinoma with liver metastasis. J Endocrinol Invest 1997; 20:230\u2013236.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"9568_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF02739952","volume":"9","author":"V Nose-Alberti","year":"1998","unstructured":"Nose-Alberti V, Mesquita MI, Martin LC, Kayath MJ. Adrenocorticotropin-producing pituitary carcinoma with expression of c-erbB-2 and high PCNA index: A comparative study with pituitary adenomas and normal pituitary tissues. Endocr Pathol 1998; 9(1):53\u201362.","journal-title":"Endocr Pathol"},{"issue":"2","key":"9568_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3835(98)00013-5","volume":"126","author":"DR Hinton","year":"1998","unstructured":"Hinton DR, Hahn JA, Weiss MH, Couldwell WT. Loss of Rb expression in an ACTH-secreting pituitary carcinoma. Cancer Lett 1998; 126(2):209\u2013214.","journal-title":"Cancer Lett"},{"key":"9568_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/BF03345482","volume":"22","author":"SA Kemink","year":"1999","unstructured":"Kemink SA, Wesseling P, Pieters GF, Verhofstad AA, Hermus AR, Smals AG. Progression of a Nelson\u2019s adenoma to pituitary carcinoma; a case report and review of the literature. J Endocrinol Invest 1999; 22:70\u201375.","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"9568_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1365-2265.2001.01322.x","volume":"55","author":"A Zahedi","year":"2001","unstructured":"Zahedi A, Booth GL, Smyth HS, et al. Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma. Clin Endocrinol (Oxf) 2001; 55(4):549\u2013556.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"9568_CR27","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3171\/jns.2002.96.2.0352","volume":"96","author":"TA Gaffey","year":"2002","unstructured":"Gaffey TA, Scheithauer BW, Lloyd RV, et al. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg 2002; 96(2):352\u2013360.","journal-title":"J Neurosurg"},{"issue":"6","key":"9568_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(06)70728-8","volume":"7","author":"S Lim","year":"2006","unstructured":"Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 2006; 7(6):518\u2013520.","journal-title":"Lancet Oncol"},{"issue":"4","key":"9568_CR29","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3171\/jns.2006.105.4.621","volume":"105","author":"CE Fadul","year":"2006","unstructured":"Fadul CE, Kominsky AL, Meyer LP et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 2006; 105(4):621\u2013626.","journal-title":"J Neurosurg"},{"issue":"5","key":"9568_CR30","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1530\/eje.1.02141","volume":"154","author":"RL Brown","year":"2006","unstructured":"Brown RL, Muzzafar T, Wollman R, Weiss RE. A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur J Endocrinol 2006; 154(5):639\u2013643.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"9568_CR31","first-page":"231","volume":"32","author":"E Guastamacchia","year":"2007","unstructured":"Guastamacchia E, Triggiani V, Tafaro E et al. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report. Minerva Endocrinol 2007; 32(3):231\u2013236.","journal-title":"Minerva Endocrinol"},{"issue":"12","key":"9568_CR32","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/0883073808319078","volume":"23","author":"A Guzel","year":"2008","unstructured":"Guzel A, Tatli M, Senturk S, Guzel E, Cayli SR, Sav A. Pituitary carcinoma presenting with multiple metastases: case report. J Child Neurol 2008; 23(12):1467\u20131471.","journal-title":"J Child Neurol"},{"key":"9568_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1477-7819-7-39","volume":"7","author":"SN Pinchot","year":"2009","unstructured":"Pinchot SN, Sippel R, Chen H. ACTH-producing carcinoma of the pituitary with refractory Cushing\u2019s Disease and hepatic metastases: a case report and review of the literature. World J Surg Oncol 2009; 7:39.","journal-title":"World J Surg Oncol"},{"key":"9568_CR34","unstructured":"Roncaroli F, Scheithauer BW, Horvath E et al. Silent Subtype 3 Carcinoma of the Pituitary: A Case Report. Neuropathol Appl Neurobiol 2009."},{"issue":"4","key":"9568_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-09-0389","volume":"161","author":"C Hagen","year":"2009","unstructured":"Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 2009; 161(4):631\u2013637.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"9568_CR36","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 2010; 95(10):4592\u20134599.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9568_CR37","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.4158\/EP12400.CR","volume":"19","author":"NL Vieira","year":"2013","unstructured":"Vieira NL, Chimelli L, Pereira PJ et al. The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma. Endocr Pract 2013; 19(6):e145-e149.","journal-title":"Endocr Pract"},{"issue":"11","key":"9568_CR38","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1210\/jc.2017-01401","volume":"102","author":"D Bengtsson","year":"2017","unstructured":"Bengtsson D, Joost P, Aravidis C, et al. Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort. J Clin Endocrinol Metab 2017; 102(11):3928\u20133932.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9568_CR39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s12022-017-9474-7","volume":"28","author":"N Tufton","year":"2017","unstructured":"Tufton N, Roncaroli F, Hadjidemetriou I, et al. Pituitary Carcinoma in a Patient with an SDHB Mutation. Endocr Pathol 2017; 28(4):320\u2013325.","journal-title":"Endocr Pathol"},{"key":"9568_CR40","doi-asserted-by":"crossref","unstructured":"Rotman LE, Vaughan TB, Hackney JR, Riley KO. Long-term survival following transformation of an adrenocorticotropic hormone secreting pituitary macroadenoma to a silent corticotroph pituitary carcinoma: Case report. World Neurosurg 2018.","DOI":"10.1016\/j.wneu.2018.11.011"},{"issue":"10","key":"9568_CR41","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"Lin AL, Jonsson P, Tabar V, et al. Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. J Clin Endocrinol Metab 2018; 103(10):3925\u20133930.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9568_CR42","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s11102-018-0872-8","volume":"21","author":"F Yoo","year":"2018","unstructured":"Yoo F, Kuan EC, Heaney AP, Bergsneider M, Wang MB. Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. Pituitary 2018; 21(3):290\u2013301.","journal-title":"Pituitary"},{"issue":"3","key":"9568_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 2018; 178(3):265\u2013276.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9568_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11102-017-0857-z","volume":"21","author":"N Lenders","year":"2018","unstructured":"Lenders N, McCormack A. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). Pituitary 2018; 21(2):217\u2013229.","journal-title":"Pituitary"},{"key":"9568_CR45","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3389\/fonc.2018.00510","volume":"8","author":"F Guo","year":"2018","unstructured":"Guo F, Wang G, Wang F, Xu D, Liu X. Identification of Novel Genes Involved in the Pathogenesis of an ACTH-Secreting Pituitary Carcinoma: A Case Report and Literature Review. Front Oncol 2018; 8:510.","journal-title":"Front Oncol"},{"issue":"6","key":"9568_CR46","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41379-018-0016-8","volume":"31","author":"O Mete","year":"2018","unstructured":"Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 2018; 31(6):900\u2013909.","journal-title":"Mod Pathol"},{"key":"9568_CR47","first-page":"842","volume":"78","author":"L Pei","year":"1994","unstructured":"Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D. H-ras mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab 1994; 78:842\u2013846.","journal-title":"J Clin Endocrinol Metab"},{"key":"9568_CR48","first-page":"89","volume":"78","author":"WY Cai","year":"1994","unstructured":"Cai WY, Alexander JM, Hedley-Whyte ET, et al. Ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab 1994; 78:89\u201393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9568_CR49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12022-007-9006-y","volume":"18","author":"Y Tanizaki","year":"2007","unstructured":"Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV. P53 gene mutations in pituitary carcinomas. Endocr Pathol 2007; 18(4):217\u2013222.","journal-title":"Endocr Pathol"},{"issue":"9","key":"9568_CR50","first-page":"2251","volume":"63","author":"D Riss","year":"2003","unstructured":"Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003; 63(9):2251\u20132255.","journal-title":"Cancer Res"},{"key":"9568_CR51","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1227\/00006123-199604000-00027","volume":"38","author":"K Thapar","year":"1996","unstructured":"Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER, Jr. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 1996; 38:765\u2013771.","journal-title":"Neurosurgery"},{"key":"9568_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00006123-199601000-00024","volume":"38","author":"K Thapar","year":"1996","unstructured":"Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996; 38:99\u2013107.","journal-title":"Neurosurgery"},{"issue":"47","key":"9568_CR53","doi-asserted-by":"publisher","first-page":"e5268","DOI":"10.1097\/MD.0000000000005268","volume":"95","author":"Z Yang","year":"2016","unstructured":"Yang Z, Zhang T, Gao H. Genetic aspects of pituitary carcinoma: A systematic review. Medicine (Baltimore) 2016; 95(47):e5268.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"9568_CR54","doi-asserted-by":"publisher","first-page":"R331","DOI":"10.1530\/ERC-14-0188","volume":"21","author":"E Monsalves","year":"2014","unstructured":"Monsalves E, Juraschka K, Tateno T, et al. The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocr Relat Cancer 2014; 21(4):R331-R344.","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"9568_CR55","doi-asserted-by":"publisher","first-page":"djv123","DOI":"10.1093\/jnci\/djv123","volume":"107","author":"RA Francois","year":"2015","unstructured":"Francois RA, Maeng K, Nawab A, Kaye FJ, Hochwald SN, Zajac-Kaye M. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors. J Natl Cancer Inst 2015; 107(8), djv123.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"9568_CR56","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364(6):514\u2013523.","journal-title":"N Engl J Med"},{"issue":"4","key":"9568_CR57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2217\/cns-2016-0011","volume":"5","author":"LE Donovan","year":"2016","unstructured":"Donovan LE, Arnal AV, Wang SH, Odia Y. Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. CNS Oncol 2016; 5(4):203\u2013209.","journal-title":"CNS Oncol"},{"issue":"8","key":"9568_CR58","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.4158\/EP14093.CR","volume":"20","author":"R Leibowitz-Amit","year":"2014","unstructured":"Leibowitz-Amit R, Mete O, Asa SL, Ezzat S, Joshua AM. Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: a case report and literature review. Endocr Pract 2014; 20(8):e145-e150.","journal-title":"Endocr Pract"},{"issue":"6","key":"9568_CR59","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364(6):501\u2013513.","journal-title":"N Engl J Med"},{"issue":"1","key":"9568_CR60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1210\/jc.2008-1836","volume":"94","author":"AM Joshua","year":"2009","unstructured":"Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma\/pheochromocytoma. J Clin Endocrinol Metab 2009; 94(1):5\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9568_CR61","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1365-2265.2012.04381.x","volume":"76","author":"G Raverot","year":"2012","unstructured":"Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 2012; 76(6):769\u2013775.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"9568_CR62","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1210\/jc.2012-2924","volume":"98","author":"T Hirohata","year":"2013","unstructured":"Hirohata T, Asano K, Ogawa Y, et al. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 2013; 98(3):1130\u20131136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9568_CR63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11912-000-0008-x","volume":"2","author":"ME Royce","year":"2000","unstructured":"Royce ME, Hoff PM, Pazdur R. Novel oral chemotherapy agents. Curr Oncol Rep 2000; 2(1):31\u201337.","journal-title":"Curr Oncol Rep"},{"issue":"61","key":"9568_CR64","doi-asserted-by":"publisher","first-page":"104046","DOI":"10.18632\/oncotarget.22001","volume":"8","author":"DH Owen","year":"2017","unstructured":"Owen DH, Alexander AJ, Konda B, et al. Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for response. Oncotarget 2017; 8(61):104046\u2013104056.","journal-title":"Oncotarget"},{"issue":"4","key":"9568_CR65","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s11102-009-0211-1","volume":"14","author":"MS Thearle","year":"2011","unstructured":"Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL. Temozolomide (Temodar(R)) and capecitabine (Xeloda(R)) treatment of an aggressive corticotroph pituitary tumor. Pituitary 2011; 14(4):418\u2013424.","journal-title":"Pituitary"},{"issue":"4","key":"9568_CR66","doi-asserted-by":"publisher","first-page":"E447","DOI":"10.1227\/NEU.0000000000000251","volume":"74","author":"BE Zacharia","year":"2014","unstructured":"Zacharia BE, Gulati AP, Bruce JN, et al. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery 2014; 74(4):E447-E455.","journal-title":"Neurosurgery"},{"issue":"2","key":"9568_CR67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.23736\/S1824-4785.17.02971-5","volume":"61","author":"M Opalinska","year":"2017","unstructured":"Opalinska M, Hubalewska-Dydejczyk A, Sowa-Staszczak A. Radiolabeled peptides: current and new perspectives. Q J Nucl Med Mol Imaging 2017; 61(2):153\u2013167.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"9568_CR68","doi-asserted-by":"publisher","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","volume":"58","author":"M Fani","year":"2017","unstructured":"Fani M, Nicolas GP, Wild D. Somatostatin Receptor Antagonists for Imaging and Therapy. J Nucl Med 2017; 58(Suppl 2):61S\u201366S.","journal-title":"J Nucl Med"},{"issue":"3","key":"9568_CR69","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11102-013-0494-0","volume":"17","author":"J Komor","year":"2014","unstructured":"Komor J, Reubi JC, Christ ER. Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary 2014; 17(3):227\u2013231.","journal-title":"Pituitary"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12022-019-9568-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-019-9568-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-019-9568-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T05:10:55Z","timestamp":1662873055000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12022-019-9568-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["9568"],"URL":"https:\/\/doi.org\/10.1007\/s12022-019-9568-5","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"31 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Asa is a member of the Medical Advisory Boards of Leica Pathology Imaging and Ibex Medical Analytics. Dr. Ezzat has served on Medical Advisory Boards of Novartis Canada, Pfizer, Ipsen, and Esai. Drs. Alshaikh and Mete have no conflicts of interest or funding to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}